[Molsidomin and intraocular pressure. No effect in healthy subjects and in glaucoma patients].
Molsidomine is a new agent in coronary therapy. It does not influence the intra-ocular pressure in healthy volunteers or in glaucoma patients. This was tested in double-blind studies in short trials and in a long term study of 3 months. The outflow facility or the visual fields were also unchanged. These results correspond closely to those obtained previously with other coronary therapeutics. Molsidomine is not dangerous for glaucoma patients.
D003327:Coronary Disease / Q000188:drug therapy*; D004341:Drug Evaluation; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008134:Long-Term Care; D009025:Morpholines / Q000627:therapeutic use*; D010069:Oxadiazoles / Q000627:therapeutic use*; D013558:Sydnones / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D009025:Morpholines; D010069:Oxadiazoles; D013558:Sydnones; D014665:Vasodilator Agents
Molsidomin und Augeninnendruck Keine Beeinflussung bei Gesunden und Glaukom-Kranken.